Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 50

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 50
---
 connection with the completion of the Kintara Merger, effective at 12:01 a.m. Eastern Time on October 18, 2024, Kintara effected a 1-for-35 reverse stock split of its common stock. Effective at 12:03 a.m. Eastern Time on October 18, 2024, the merger was completed, and effective at 12:04 a.m. Eastern Time on October 18, 2024,  Kintara Therapeutics, Inc. was renamed “TuHURA Biosciences, Inc.”

On December 12, 2024, we announced that we had entered into a definitive merger agreement to acquire Kineta, Inc. (“Kineta”), a Delaware corporation that is developing KVA12123, an anti-VISTA antibody checkpoint inhibitor designed to reverse VISTA immune suppression and remodel the tumor microenvironment to overcome acquired resistance to immunotherapies.  The merger agreement (the “Kineta Merger Agreement”) was entered into among our company, Kineta,  Hura Merger Sub I, Inc., a Delaware corporation and direct wholly owned subsidiary of ours (“Hura Merger Sub I”), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly owned subsidiary of ours (“Hura Merger Sub II”), and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta. The Kineta Merger contemplates the acquisition of Kineta through a merger transaction pursuant to which Hura Merger Sub I will (a) merge with and into Kineta (the “First Merger”), with Kineta being the surviving corporation of the First Merger (also known as the “Surviving Entity”) and (b) immediately following the First Merger and as part of the same overall transaction as the First Merger, the Surviving Entity will merge with and into Hura Merger Sub II (the “Second Merger”, and together with the First Merger, the “Kineta Merger”), with Hura Merger Sub II being the surviving company of the Second Merger. 

At the effective time of the First Merger, and subject to the terms and conditions of the Kineta Merger Agreement, each share of Kineta’s common stock, par value $0.001 per share (“Kineta Common Stock”) issued and outstanding immediately prior to the effective time of the First Merger will be converted automatically into and will represent the right to receive